Editor’s Note: Occasionally, an opportunity comes to our attention that we believe readers like you will find valuable. The message below from one of our partners is one we believe you should take a close look at.

Dear Reader,

On December 13, 2022, a Big Pharma giant quietly bought one AI-designed drug for $4 billion.

That makes it the biggest deal for an AI-designed drug in history.

But very few people even know about it...yet.

Even leading investors in the U.S. have no idea.

And they don't know that this tiny AI-biotech designed the drug.

But this won't stay quiet much longer.

On January 9, 2023, ristol Myers Squibb signed a $2.7 billion deal to have their AI-platform develop six new drugs.

On October 6, 2022, Eli Lilly signed a $425 million deal to have their AI-platform develop a new drug.

These seven drugs alone could bring $28 billion to this little-known company.

That doesn't include deals they signed with Sanofi, Nimbus Therapeutics, Petra Pharma and others.

Wall Street doesn't yet grasp how this company is quietly revolutionizing the drug discovery business...

Which is why I believe this will be the biggest AI winner you never heard of.

Get the name of the stock here...while it's still a small-cap >>>

"The Buck Stops Here,"

Trading involves risk. The information provided is NOT trading advice. Neither the Editors, the Publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the newsletter. Past performance is no guarantee of future performance. This recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability for any purchase or order made from any company or entity mentioned or recommended in this email.

The information provided is for educational purposes only. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Actual results may differ. Nothing here constitutes a recommendation respecting the particular security illustrated.